Cargando…

Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma

Detalles Bibliográficos
Autor principal:	Kudo, Masatoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396100/ https://www.ncbi.nlm.nih.gov/pubmed/36016731 http://dx.doi.org/10.21037/hbsn-22-143

Ejemplares similares

Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study
por: Kelley, Robin Kate, et al.
Publicado: (2021)

Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma
por: Song, Xuyang, et al.
Publicado: (2023)

An Uncommon Case of Myocarditis Secondary to Durvalumab Plus Tremelimumab
por: Diaz-Rodriguez, Porfirio E, et al.
Publicado: (2023)

Identification of characteristics predictive of long-term survival with durvalumab or durvalumab plus tremelimumab in metastatic urothelial carcinoma
por: Alt, Marie, et al.
Publicado: (2023)

Durvalumab Plus Tremelimumab in Solid Tumors: A Systematic Review
por: Arru, Caterina, et al.
Publicado: (2021)

Atezolizumab plus bevacizumab and tremelimumab plus durvalumab: how should we choose these two immunotherapy regimens for advanced hepatocellular carcinoma?
por: Hatanaka, Takeshi, et al.
Publicado: (2022)

Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin
por: Capdevila, J., et al.
Publicado: (2023)

Durvalumab and tremelimumab combination therapy versus durvalumab or tremelimumab monotherapy for patients with solid tumors: A systematic review and meta-analysis
por: Wang, Bi-Cheng, et al.
Publicado: (2020)

Effects of combination treatment with durvalumab plus tremelimumab on the tumor microenvironment in non-small-cell lung carcinoma
por: Cheng, Li, et al.
Publicado: (2021)

Evidence to Date: Clinical Utility of Tremelimumab in the Treatment of Unresectable Hepatocellular Carcinoma
por: Ahmed, Zunirah, et al.
Publicado: (2023)

Myocarditis with tremelimumab plus durvalumab combination therapy for endometrial cancer: A case report
por: Mahmood, Syed S., et al.
Publicado: (2018)

Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma
por: Kudo, Masatoshi
Publicado: (2022)

Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma
por: Bahig, Houda, et al.
Publicado: (2019)

Selection of Systemic Treatment Regimen for Unresectable Hepatocellular Carcinoma: Does Etiology Matter?
por: Kudo, Masatoshi
Publicado: (2022)

Safety and tolerability of first‐line durvalumab with tremelimumab and chemotherapy in esophageal squamous cell carcinoma
por: Lee, Dae Ho, et al.
Publicado: (2023)

Phase II Trial of Combined Durvalumab Plus Tremelimumab with Proton Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Kim, Hana, et al.
Publicado: (2023)

Phase II, randomized, open-label study of durvalumab (MEDI4736) or tremelimumab monotherapy, or durvalumab + tremelimumab, in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CONDOR
por: Gilbert, Jill, et al.
Publicado: (2015)

Two Cases of Advanced Hepatocellular Carcinoma Who Responded Well to the Combination of Durvalumab Plus Tremelimumab After Disease Progression During Atezolizumab Plus Bevacizumab Therapy Under Bevacizumab Withdrawal
por: Kawamura, Yusuke, et al.
Publicado: (2023)

Sorafenib plus transarterial chemoembolization for unresectable hepatocellular carcinoma
por: Tsilimigras, Diamantis I., et al.
Publicado: (2020)

A phase II trial of durvalumab and tremelimumab in metastatic, non‐urothelial carcinoma of the urinary tract
por: Sarfaty, Michal, et al.
Publicado: (2020)

Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG‐LU16‐07
por: Kim, Miso, et al.
Publicado: (2020)

Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trial
por: Ogasawara, Sadahisa, et al.
Publicado: (2022)

A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer
por: Santa-Maria, Cesar August, et al.
Publicado: (2018)

Adverse Events and Tolerability of Combined Durvalumab and Tremelimumab versus Durvalumab Alone in Solid Cancers: A Systematic Review and Meta-Analysis
por: Fahmy, Omar, et al.
Publicado: (2022)

Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study
por: Hamid, Omid, et al.
Publicado: (2023)

Adverse events induced by durvalumab and tremelimumab combination regimens: a systematic review and meta-analysis
por: Matsumoto, Hiromi, et al.
Publicado: (2023)

Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Wildsmith, Sophie, et al.
Publicado: (2023)

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
por: Finn, Richard S., et al.
Publicado: (2020)

Progressive hypoventilation due to mixed CD8(+) and CD4(+) lymphocytic polymyositis following tremelimumab - durvalumab treatment
por: John, Sooraj, et al.
Publicado: (2017)

Tremelimumab
Publicado: (2012)

MOVIE: a phase I, open-label, multicenter study to evaluate the safety and tolerability of metronomic vinorelbine combined with durvalumab plus tremelimumab in patients with advanced solid tumors
por: Vicier, C., et al.
Publicado: (2022)

First-line tremelimumab plus durvalumab and chemotherapy versus chemotherapy alone for metastatic non-small cell lung cancer: a cost-effectiveness analysis in the United States
por: Liu, Wenjie, et al.
Publicado: (2023)

Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience
por: Hiraoka, Atsushi, et al.
Publicado: (2021)

Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN
por: Paz-Ares, L., et al.
Publicado: (2022)

Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study
por: Calabrò, Luana, et al.
Publicado: (2021)

Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer
por: Schofield, Darren J., et al.
Publicado: (2021)

First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial
por: Thibaudin, Marion, et al.
Publicado: (2023)

Adjuvant Atezolizumab-Bevacizumab after Resection or Ablation for Hepatocellular Carcinoma
por: Kudo, Masatoshi
Publicado: (2023)

A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D
por: Lee, Jung-Yun, et al.
Publicado: (2019)

Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial
por: Li, Daneng, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_uooio4l213gkb6eqfoq0i6k0jg